A sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1290-1300

  Martinez Gil L ^a   Goff, P H ^a   Hai, R ^a   Garcia Sastre A ^a   Shaw, M L ^a   Palese, P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; VIRUS RNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; RNA TRANSCRIPTION; SENDAI VIRUS; VIRAL GENE DELIVERY SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DEAD-BOX RNA HELICASES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; RNA, VIRAL; SENDAI VIRUS; VACCINES, INACTIVATED;

EID: 84873046317     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02338-12     Document Type: Article

References (44)

1. Yan N, Chen ZJ. 2012. Intrinsic antiviral immunity. Nat. Immunol. 13:214-222.
2. Kumar H, Kawai T, Akira S. 2011. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30:16-34.
3. García-Sastre A, Biron CA. 2006. Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312:879-882.
4. Versteeg GA, García-Sastre A. 2010. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 13:508-516.
5. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3:920-940.
6. Baum A, García-Sastre A. 2011. Differential recognition of viral RNA by RIG-I. Virulence 2:166-169.
7. Loo Y, Gale MJ. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680-692.
8. Kato H, Takahasi K, Fujita T. 2011. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol. Rev. 243:91-98.
9. González-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-135.
10. Seya T, Kasamatsu J, Azuma M, Shime H, Matsumoto M. 2011. Natural killer cell activation secondary to innate pattern sensing. J. Innate Immun. 3:264-273.
11. Huber JP, Farrar JD. 2011. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132:466-474.
12. Beignon A, Skoberne M, Bhardwaj N. 2003. Type I interferons promote cross-priming: more functions for old cytokines. Nat. Immunol. 4:939- 941.
13. Bodnár A, Nizsalóczki E, Mocsár G, Szalóki N, Waldmann TA, Damjanovich S, Vámosi G. 2008. A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. Immunol. Lett. 116:117-125.
14. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. 2007. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13:4677- 4685.
15. Tovey MG, Lallemand C. 2010. Adjuvant activity of cytokines. Methods Mol. Biol. 626:287-309.
16. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. 2003. Enhancement of antigen-specific immunity via the tlr4 ligands mpl adjuvant and ribi 529. Expert Rev. Vaccines 2:219-229.
17. Kolakofsky D. 1976. Isolation and characterization of Sendai virus DIRNAs. Cell 8:547-555.
18. Johnston MD. 1981. The characteristics required for a Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J. Gen. Virol. 56:175-184.
19. Miller DK, Lenard J. 1982. Ultraviolet-irradiated vesicular stomatitis virus and defective-interfering particles are similar non-specific inhibitors of virus infection. J. Gen. Virol. 60:327-333.
20. Yount JS, Kraus TA, Horvath CM, Moran TM, López CB. 2006. A novel role for viral-defective interfering particles in enhancing dendritic cell maturation. J. Immunol. 177:4503- 4513.
21. Baum A, Sachidanandam R, García-Sastre A. 2010. Preference of RIG-I for short viralRNAmolecules in infected cells revealed by next-generation sequencing. Proc. Natl. Acad. Sci. U. S. A. 107:16303-16308.
22. Hai R, Martínez-Sobrido L, Fraser KA, Ayllon J, García-Sastre A, Palese P. 2008. Influenza B virus ns1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82:10580-10590.
23. Nguyen DN, Kim P, Martínez-Sobrido L, Beitzel B, García-Sastre A, Langer R, Anderson DG. 2009. A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol. Bioeng. 103:664-675.
24. Strahle L, Garcin D, Kolakofsky D. 2006. Sendai virus defectiveinterfering genomes and the activation of interferon-beta. Virology 351: 101-111.
25. Takahasi K, Yoneyama M, Nishihori T, Hirai R, Kumeta H, Narita R, Gale MJ, Inagaki F, Fujita T. 2008. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell 29:428-440.
26. Uzri D, Gehrke L. 2009. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J. Virol. 83:4174- 4184.
27. Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80:9192-9199.
28. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M. 1998. Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J. Exp. Med. 188:2091-2097.
29. Desmyter J, Melnick JL, Rawls WE. 1968. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 2:955-961.
30. Emeny JM, Morgan MJ. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43:247-252.
31. Falcoff E, Falcoff R, Cherby J, Florent J, Lunel J, Ninet L, De Ratuld Y, Tissier R, Vuillemin B, Werner GH. 1973. Double-stranded ribonucleic acid from mengo virus: production, characterization, and interferoninducing and antiviral activities in comparison with polyriboinosinicpolyribocytidylic acid. Antimicrob. Agents Chemother. 3:590-598.
32. Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. 1995. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.Antimicrob. Agents Chemother. 39:2574- 2576.
33. Higgins DA, Carlson JR, Van Nest G. 1996. Mf59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14:478-484.
34. Valensi JP, Carlson JR, Van Nest GA. 1994. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing mf59 oil emulsion and other advanced adjuvants. J. Immunol. 153:4029-4039.
35. Toporovski R, Morrow MP, Weiner DB. 2010. Interferons as potential adjuvants in prophylactic vaccines. Expert Opin. Biol. Ther. 10:1489- 1500.
36. Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ. 2011. Innate and adaptive immune responses to viral infection and vaccination. Curr. Opin. Virol. 1:226-232.
37. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. 2008. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 3:352-363.
38. Alving CR, Peachman KK, Rao M, Reed SG. 2012. Adjuvants for human vaccines. Curr. Opin. Immunol. 24:310-315.
39. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. 2000. A toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
40. De Clercq E, Stollar BD, Thang MN. 1978. Interferon inducing activity of polyinosinic acid. J. Gen. Virol. 40:203-212.
41. Luster AD, Ravetch JV. 1987. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1084-1097. 42. Luster AD, Ravetch JV. 1987. Genomic characterization of a gammainterferon- inducible gene (IP-10) and identification of an interferoninducible hypersensitive site. Mol. Cell. Biol. 7:3723-3731.
42. Luster AD, Ravetch JV. 1987. Genomic characterization of a gammainterferon- inducible gene (IP-10) and identification of an interferoninducible hypersensitive site. Mol. Cell. Biol. 7:3723-3731.
43. Reuter S, Dehzad N, Martin H, Böhm L, Becker M, Buhl R, Stassen M, Taube C. 2012. Tlr3 but not tlr7/8 ligand induces allergic sensitization to inhaled allergen. J. Immunol. 188:5123-5131.
44. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. 2006. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 13:981-990.